Scalper1 News
Big-cap biotech Alexion Pharmaceuticals (ALXN) beat Q1 estimates and raised its full-year-earnings guidance Thursday, sending the stock up 3% in morning trading on the stock market. Fellow biotech giant Celgene (CELG) missed, however. Alexion reported earnings of $1.53 a share, up 135% from the year-earlier quarter and 27 cents above analysts’ consensus. Sales rose 67% to $566.6 million, topping estimates by nearly $7 million. For this year, the Scalper1 News
Scalper1 News